ClinicalTrialsFinder
RecruitingPhase 2NCT06509334

Trial of JYB1904 in Chronic Spontaneous Urticaria.

A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Adult Patients with Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines

Sponsor

Jemincare

Enrollment

135 participants

Start Date

Aug 4, 2024

Study Type

INTERVENTIONAL

Conditions

Chronic Spontaneous Urticaria

Summary

This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JYB1904, a drug called JYB1904, and others for people with chronic spontaneous urticaria. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJYB1904

Participants will receive JYB1904 at week0 and receive placebo at week4,8,12

DRUGJYB1904

Participants will receive JYB1904 at week0,8 and receive placebo at week4,12

DRUGOmalizumab

Participants will receive Omalizumab every 4 weeks for 12 weeks

Locations(1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06509334

Related Trials

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT0721961569 locations

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT0567745166 locations

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT0725639234 locations

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

NCT074082191 location

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT075409101 location